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Purpose: To report a case of multifocal serous retinal detachments associated with
pimasertib.
Methods: The authors report a 26-year-old patient who developed bilateral multifocal
serous retinal detachments appearing 2 days after starting pimasertib (as part of a clinical
trial investigating its use in low-grade metastatic ovarian cancer) and rapidly resolving
3 days after stopping it.
Conclusion: The mechanism of MEK inhibitor induced visual toxicity remains unclear.
The pathophysiology of multifocal serous retinal detachments as a complication of
pimasertib is still poorly understood.
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Case Report
This unique case demonstrates bilateral serous retinal detach-
ments as a side effect of pimasertib. Pimasertib is an orally
bioavailable MEK 1 and 2 inhibitor with potential antineoplastic
activity, that is, currently used in clinical trials for ovarian cancer.
A 26-year-old woman, known to have metastatic low-grade serous
ovarian cancer, started complaining of blurred vision 2 days after
starting pimasertib. This was prescribed as part of a clinical trial,
investigating the use of pimasertib versus placebo in the treatment of
low-grade metastatic ovarian cancer. Pimasertib is given as a 60-mg
tablet daily for 21 days followed by 7 days break and then the cycle is
restarted. Snellen visual acuity at presentation was 20/25+2 in each eye,
intraocular pressure was 14 mmHg, and the anterior segment was
unremarkable. Fundoscopy showed multifocal serous retinal detach-
ment in both eyes (Figure 1). Optical coherence tomography
demonstrated striking bilateral, multifocal serous retinal detachments
(Figure 2, A and B). There was no history of steroid use.
Three days after emergently stopping the pimasertib due to her
ocular complaint, her vision rapidly returned to normal. Snellen visual
acuity had improved to 20/20 in each eye and fundoscopy revealed
resolution of the serous retinal detachments (Figure 3). Optical
coherence tomography showed near complete resolution of the serous
retinal detachments (Figure 4, A and B). Intravenous ﬂuorescein fundus
angiography was normal after stopping the medication (Figure 5).
Pimasertib is a MEK 1 and 2 inhibitor that modulates mitogen-
activated protein kinases, which are a family of ubiquitous
eukaryotic signal transduction enzymes that link extracellular
stimuli to intracellular gene expression pathways allowing for
various cellular responses, including adaptation and survival.1 The
classic mitogen-activated protein kinase cascade, the Ras/Raf/
MEK/ERK cascade, is initiated by the binding of a ligand such
as a growth factor, mitogen, or cytokine to its receptor at the cell
surface. This cascade is now identiﬁed as a target opportunity for
the treatment of low-grade ovarian carcinoma.
Pimasertib has been used in clinical trials for the treatment of
various types of cancer. Most common adverse events observed
include diarrhea, rash, asthenia, anorexia, nausea, vomiting,
peripheral edema, anemia, and visual disturbances including retinal
vein occlusion, serous retinal detachment, and macular edema
(Table 1). The underlying pathology for central serous retinopathy
is reversible after drug interruption followed by dose reduction.2,3
The mechanism of MEK inhibitor induced ocular toxicity
remains unclear. Many of the molecules targeted by anticancer
agents are also expressed in ocular tissues, which can explain the
ocular toxicity causes by such medications. There is evidence that
the mitogen-activated protein kinase pathway regulates tight
junctions between retinal pigment epithelial cells so that MEK
inhibitors may interfere with ﬂuid transport, resulting in the
accumulation of ﬂuid beneath the retina.4
To our knowledge, this is the ﬁrst case that describes bilateral,
multifocal central serous retinopathy appearing 2 days after starting
pimasertib for ovarian cancer and rapidly resolving 3 days after
stopping pimasertib. Multifocal serous retinal detachments have
been reported with the use of other MEK 1 and 2 inhibitors.4 The
pathophysiology of this complication is still poorly understood.
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Fig. 1. Fundoscopic exam
showing multi-foci serous reti-
nal detachments.
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Fig. 2. A. Optical coherence tomography of the right
eye showing multifocal serous retinal detachments. B.
Optical coherence tomography of the left eye showing
multifocal serous retinal detachments.
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Fig. 3. Fundoscopic examina-
tion showing resolution of
serous retinal detachments.
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Fig. 4. A. Optical coherence tomography of the right
eye showing complete resolution of serous retinal de-
tachments after completing pimasertib course. B.
Optical coherence tomography of the left eye showing
almost complete resolution of serous retinal detach-
ments after completing pimasertib course.
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Fig. 5. Intravenous fundus
ﬂuorescein angiogram of both
eyes was normal 3 days after
stopping pimasertib.
Table 1. Current MEK Inhibitors Clinical Trials and Associated Percentages of Ocular Toxicity as Well as the Most
Common Side Effects
Clinical Trial % of Ocular Toxicity Most Common Side Effects
CI-10405 8.9 Nausea, diarrhea, rash, and fatigue
AZD 6244 (oral capsule)6 12.2 Nausea, diarrhea, rash, fatigue, and edema
GSK 11202127 9.0 Diarrhea, rash, fatigue, edema, and dermatitis
RO51267668 42.3 Diarrhea, rash, edema, elevated creatinine, and blurred vision
PD-03259019 10.6 Nausea, diarrhea, rash, fatigue, and edema
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